Page number 1
NO 3 – 2020 SHARE magazine Quarterly investor update Phase 2 trial successfully completed with ziltivekimab
NO 3 – 2020 SHARE magazine Quarterly investor update Phase 2 trial successfully completed with ziltivekimab